Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 6/20 | 0.43 |
| ▸ | FLT4 | P35916 | 6/20 | 0.43 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | PYGL | P06737 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419497 | 1.00 | FLT1 (0.43) | FLT1FLT4KDRMAPTCTNNB1 | |
| SCHEMBL4620071 | 0.89 | FLT1 (0.56) | FLT1FLT4KDRRAB9ASMN1; SMN2 | |
| SCHEMBL4620080 | 0.89 | FLT1 (0.56) | FLT1FLT4KDRRAB9ASMN1; SMN2 | |
| SCHEMBL4619085 | 0.87 | FLT1 (0.48) | FLT1FLT4KDRHPGDRAB9A | |
| SCHEMBL4619090 | 0.87 | FLT1 (0.48) | FLT1FLT4KDRHPGDRAB9A | |
| SCHEMBL5409698 | 0.85 | FLT1 (0.47) | FLT1FLT4KDRHPGDPYGL | |
| SCHEMBL5409711 | 0.85 | FLT1 (0.47) | FLT1FLT4KDRHPGDPYGL | |
| SCHEMBL5417298 | 0.85 | CYP1A1 (0.41) | FLT1FLT4KDRMAPTRAB9A | |
| SCHEMBL5417287 | 0.85 | CYP1A1 (0.41) | FLT1FLT4KDRMAPTRAB9A | |
| SCHEMBL5411580 | 0.84 | FLT1 (0.51) | FLT1FLT4KDRMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | FLT1 4126/4885FLT4 4438/4885KDR 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.